Our Story
Our beginning...
In preclinical research led by Søren P. Sheikh, MD, PhD, adipose-derived stem cells demonstrated promising efficacy in a rat model of erectile dysfunction.
Motivated by these results, Søren set out to develop a safe, effective, and accessible stem-cell therapy for ED—a disease affecting many men yet offering few truly curative options.
In 2016, the Danish Medicines Agency approved a Phase I trial of autologous adipose-derived stem cells for treating erectile dysfunction after radical prostatectomy.
In the Phase I trial, patients with complete erectile dysfunction unresponsive to PDE-5 inhibitors such as Viagra achieved notable outcomes: eight of eleven urine-continent men recovered erectile function and could resume sexual activity six months after treatment.
However, this autologous approach depended on liposuction and on-site cell processing, restricting access. To overcome these hurdles, Søren developed standardised protocols for producing allogeneic, off-the-shelf stem cells that retain—or improve—their therapeutic potency.
Since founding Blue Cell Therapeutics, Søren has built a team to develop this off-the-shelf allogeneic stem-cell therapy—Blue Cell Therapy—a true curative option for erectile dysfunction.
Today, our company unites an experienced management team with a committed cadre of scientists, forming a highly proficient organization.
